Results 111 to 120 of about 58,036 (310)

Dopa responsiveness in Parkinson’s disease [PDF]

Dopa responsiveness in Parkinson’s disease
Abstract Background Dopaminergic responsiveness is a defining feature of Parkinson's disease (PD). However, there is limited information on how this evolves over time. Objectives To examine serial dopaminergic ...
Sacha E. Gandhi, Anahita Nodehi, Michael A. Lawton, Katherine A. Grosset, Vicky Marshall, Yoav Ben‐Shlomo, Donald G. Grosset   +6 more
openaire   +3 more sources

A systematic review on drugs absorption modifications after eradication in Helicobacter pylori positive patients undergoing replacement therapy

, 2015
Background & Aims: Helicobacter pylori (H. pylori) infection has been suggested as a cause of impaired drug absorption. This infection leads to alteration of the gastric acid secretion that may change the conformational characteristics of drugs and their
Fiorini, G., Hughes, Elizabeth, Fiorini, Giulia, Vaira, Dino, Bland, John Martin, Castelli, V., Vaira, D., Hughes, E., Bland, J.M., Castelli, Valentina, VAIRA, BERARDINO   +10 more
core   +1 more source

Ketogenic diet for infantile epileptic spasms

Epilepsia Open, EarlyView.
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury, Anamika Choudhary, Andy Cheuk‐Him Ng, Cezar Gavrilovici   +3 more
wiley   +1 more source

Effects of Subchronic Treatment With Selegiline on L-DOPA-Induced Increase in Extracellular Dopamine Level in Rat Striatum

Journal of Pharmacological Sciences, 2006
.: Selegiline is used an adjunct to L-DOPA therapy. We investigated extracellular striatal dopamine (DA) level in awake rats treated with L-DOPA and/or selegiline using a microdialysis method. Rats given 10 mg/kg, i.p.
Adachi Kouichi, Miwa Hideto, Kusumoto Haruko, Shimazu Seiichiro, Kondo Tomoyoshi   +4 more
doaj   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

Metabolism of protein-bound DOPA in mammals

, 2000
Protein-bound 3,4-dihydroxyphenylalanine (DOPA) can be generated in mammalian cells by both controlled enzymatic pathways, and by uncontrolled radical reactions.
Roger T Dean, Dean, RT, Kenneth J Rodgers, Rodgers, KJ   +3 more
core   +2 more sources

A Bioinspired Dopamine‐Amorphous Calcium Phosphate Coating on Titanium Implant for Osteogenesis and Angiogenesis

Advanced Materials Interfaces
Titanium (Ti) is widely used in dental implantation. However, their lack of biological activity causes significant clinical risks associated with immediate loading and early osteointegration failure.
Wenjing Wu, Yanhuizhi Feng, Bing Ni
doaj   +1 more source

Hypervision Proton Surgery: The Future Direction of Proton Therapy

iNew Medicine, EarlyView.
ABSTRACT Proton beams provide unique physical advantages characterized by a low entrance dose, negligible exit dose, and a sharp Bragg peak, which enable superior sparing of normal tissues and support safe dose escalation for improved tumor control. However, conventional photon‐based fractionation remains widely used in proton therapy, where prolonged ...
Li Li, Shuanghu Yuan
wiley   +1 more source

Functionalization of prosthetic implants with mussel-derived DOPA protein to enhance osseointegration

openIl successo clinico a lungo termine degli impianti protesici endossei dipende in larga misura dalla loro capacità di integrarsi stabilmente con il tessuto osseo circostante.
GOVONI, ESMERALDA
core  

L-Dopa and Brain Serotonin System Dysfunction

, 2015
L-dopa is used to treat the motor symptoms associated with Parkinson’s disease, a neurodegenerative movement disorder characterized by a loss of dopamine neurons.
Bryan Yamamoto, Branden J. Stansley, Branden Stansley, Bryan K. Yamamoto   +3 more
core   +1 more source